速递｜诺和泰®中国说明书更新：纳入外周动脉疾病（PAD）获益

Core Viewpoint - Novo Nordisk's GLP-1 receptor agonist, Ozempic® (semaglutide injection), has received approval from the National Medical Products Administration (NMPA) in China for an updated label that includes benefits for patients with peripheral artery disease (PAD) [4] Group 1: Clinical Trial Results - The update is based on the STRIDE clinical trial results, which demonstrated that Ozempic® 1.0mg significantly improves walking ability in patients with type 2 diabetes and PAD, increasing the maximum walking distance by 13% and showing an average treatment difference of 39.9 meters [4] Group 2: Treatment Options - Type 2 diabetes is a primary risk factor for PAD, with nearly one-third of PAD patients also having type 2 diabetes. Currently, there are limited treatment options specifically aimed at improving walking ability in this population, making the updated label for Ozempic® a new treatment choice for these patients [5] Group 3: Progress of Ozempic® in China - Since its launch, Ozempic® has progressed through various indications in China, receiving dual indications for glycemic control and cardiovascular event reduction in 2021, becoming the first and only GLP-1 RA weekly formulation with cardiovascular indications in the country. It was included in the national medical insurance the same year [6] - By July 2025, it will gain an additional indication for chronic kidney disease, making it the first GLP-1 drug in China with three indications: diabetes, cardiovascular, and kidney [6] - The inclusion of PAD benefits marks an upgrade in its "multiple protections" for Chinese patients [6]